{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:38:22Z","timestamp":1792597102035,"version":"4.5.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Laboratory Medicine"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.cll.2026.07.010","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:49:19Z","timestamp":1787777359000},"page":"699-715","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-Seizure Medication Monitoring in Pediatric Patients"],"prefix":"10.1016","volume":"46","author":[{"given":"Grace R.","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa M.","family":"Way","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.cll.2026.07.010_bib1","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1212\/CON.0000000000001087","article-title":"Seizures and epilepsy in childhood","volume":"28","author":"Gogou","year":"2022","journal-title":"Continuum (Minneap Minn)"},{"issue":"4","key":"10.1016\/j.cll.2026.07.010_bib2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/epi.12550","article-title":"ILAE official report: a practical clinical definition of epilepsy","volume":"55","author":"Fisher","year":"2014","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.cll.2026.07.010_bib3","doi-asserted-by":"crossref","first-page":"e15523","DOI":"10.1111\/ped.15523","article-title":"Antiseizure medication treatment outcomes in new-onset pediatric epilepsy","volume":"65","author":"Itamura","year":"2023","journal-title":"Pediatr Int"},{"issue":"2","key":"10.1016\/j.cll.2026.07.010_bib4","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1212\/CON.0000000000000712","article-title":"Antiepileptic drug treatment of epilepsy in children","volume":"25","author":"Moosa","year":"2019","journal-title":"Continuum"},{"issue":"7","key":"10.1016\/j.cll.2026.07.010_bib5","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3390\/ph16070945","article-title":"A 5-Year study of antiseizure medications (ASMs) monitoring in patients with neuropsychiatric disorders in an Italian clinical center","volume":"16","author":"Biso","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"5","key":"10.1016\/j.cll.2026.07.010_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.bj.2023.100680","article-title":"Clinical impact of therapeutic drug monitoring for newer anti-seizure medications in patients with epilepsy: a real-world observation study","volume":"47","author":"Lim","year":"2024","journal-title":"Biomed J"},{"key":"10.1016\/j.cll.2026.07.010_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.spen.2010.10.002","article-title":"Developmental pharmacokinetics","volume":"17","author":"Anderson","year":"2010","journal-title":"Semin Pediatr Neurol"},{"key":"10.1016\/j.cll.2026.07.010_bib8","series-title":"The treatment of epilepsy","first-page":"489","article-title":"Lacosamide","author":"Sachdeo","year":"2015"},{"issue":"12","key":"10.1016\/j.cll.2026.07.010_bib9","article-title":"Long-term management of pediatric chronic diseases: improving quality of life and reducing hospital admissions in children with asthma, cystic fibrosis, diabetes, and epilepsy","volume":"16","author":"Khan","year":"2024","journal-title":"Cureus"},{"issue":"Suppl 2","key":"10.1016\/j.cll.2026.07.010_bib10","first-page":"S23","article-title":"Hepatic considerations in the use of antiepileptic drugs","volume":"28","author":"Dreifuss","year":"1987","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.cll.2026.07.010_bib11","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.clinthera.2024.01.008","article-title":"Physiologically based pharmacokinetic modeling of lacosamide in patients with hepatic and renal impairment and pediatric populations to support pediatric dosing optimization","volume":"46","author":"Zhu","year":"2024","journal-title":"Clin Ther"},{"issue":"7","key":"10.1016\/j.cll.2026.07.010_bib12","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1124\/dmd.116.069559","article-title":"Role of quantitative clinical pharmacology in pediatric approval and labeling","volume":"44","author":"Mehrotra","year":"2016","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.cll.2026.07.010_bib13","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.seizure.2005.12.009","article-title":"Antiepileptic drugs and liver disease","volume":"15","author":"Ahmed","year":"2006","journal-title":"Seizure"},{"key":"10.1016\/j.cll.2026.07.010_bib14","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3389\/fneur.2013.00192","article-title":"Clinical pharmacology and pharmacokinetics of levetiracetam","volume":"4","author":"Wright","year":"2013","journal-title":"Front Neurol"},{"key":"10.1016\/j.cll.2026.07.010_bib15","doi-asserted-by":"crossref","first-page":"149s","DOI":"10.18433\/jpps30081","article-title":"Therapeutic drug monitoring of levetiracetam in select populations","volume":"21","author":"Jarvie","year":"2018","journal-title":"J Pharm Pharm Sci"},{"issue":"218","key":"10.1016\/j.cll.2026.07.010_bib16","article-title":"Principal component analysis of antiseizure medication-induced hostility\/aggression and factor analysis of levetiracetam using the food and drug administration adverse event reporting system","volume":"21","author":"Hosoya","year":"2025","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.cll.2026.07.010_bib17","unstructured":"UCB, Inc. (2024). Keppra [Package Insert]. Product Label, U. Inc, Editor. 2024. Available at: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/Keppra."},{"key":"10.1016\/j.cll.2026.07.010_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2022.109065","article-title":"Current evidence for adjunct pyridoxine (vitamin B6) for the treatment of behavioral adverse effects associated with levetiracetam: a systematic review","volume":"140","author":"Besag","year":"2023","journal-title":"Epilepsy Behav"},{"issue":"9","key":"10.1016\/j.cll.2026.07.010_bib19","doi-asserted-by":"crossref","first-page":"964","DOI":"10.3109\/15563650.2014.965828","article-title":"An 11-year review of levetiracetam ingestions in children less than 6 years of age","volume":"52","author":"Lewis","year":"2014","journal-title":"Clin Toxicol (Phila)"},{"issue":"4","key":"10.1016\/j.cll.2026.07.010_bib20","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s40272-019-00332-y","article-title":"Safety and tolerability of adjunctive brivaracetam in pediatric patients < 16 years with epilepsy: an open-label trial","volume":"21","author":"Liu","year":"2019","journal-title":"Paediatr Drugs"},{"issue":"1","key":"10.1016\/j.cll.2026.07.010_bib21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1124\/dmd.107.017129","article-title":"Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects","volume":"36","author":"Sargentini-Maier","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"1\u201302","key":"10.1016\/j.cll.2026.07.010_bib22","first-page":"e1","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.cll.2026.07.010_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.107966","article-title":"Mechanisms of action of currently used antiseizure drugs","volume":"168","author":"Sills","year":"2020","journal-title":"Neuropharmacology"},{"issue":"22","key":"10.1016\/j.cll.2026.07.010_bib24","doi-asserted-by":"crossref","first-page":"5396","DOI":"10.3390\/jcm10225396","article-title":"Therapeutic drug monitoring of carbamazepine: a 20-Year observational study","volume":"10","author":"Grze\u015bk","year":"2021","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.cll.2026.07.010_bib25","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0022-3476(85)80689-2","article-title":"Carbamazepine and carbamazepine-10,11-epoxide serum concentrations in epileptic children","volume":"106","author":"Furlanut","year":"1985","journal-title":"J Pediatr"},{"issue":"3","key":"10.1016\/j.cll.2026.07.010_bib26","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/00007691-199606000-00011","article-title":"Displacement of valproic acid and carbamazepine from protein binding in normal and uremic sera by tolmetin, ibuprofen, and naproxen: presence of inhibitor in uremic serum that blocks valproic acid-naproxen interactions","volume":"18","author":"Dasgupta","year":"1996","journal-title":"Ther Drug Monit"},{"issue":"6","key":"10.1016\/j.cll.2026.07.010_bib27","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/00007691-199612000-00006","article-title":"Relationships between carbamazepine-diol, carbamazepine-epoxide, and carbamazepine total and free steady-state concentrations in epileptic patients: the influence of age, sex, and comedication","volume":"18","author":"Svinarov","year":"1996","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.cll.2026.07.010_bib28","unstructured":"Novartis Pharmaceuticals Corporation. 2025. Tegretol [Package Insert]. Available at: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/."},{"key":"10.1016\/j.cll.2026.07.010_bib29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pediatrneurol.2017.09.013","article-title":"Antiepileptic drugs and liver disease","volume":"77","author":"Vidaurre","year":"2017","journal-title":"Pediatr Neurol"},{"issue":"5","key":"10.1016\/j.cll.2026.07.010_bib30","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1365-2125.2009.03398.x","article-title":"Acute oxcarbazepine overdose in an autistic boy","volume":"67","author":"Pedrini","year":"2009","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.cll.2026.07.010_bib31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1212\/cont.0000000000001521","article-title":"Update on antiseizure medications 2025","volume":"31","author":"Abou-Khalil","year":"2025","journal-title":"Continuum (Minneap Minn)"},{"key":"10.1016\/j.cll.2026.07.010_bib32","series-title":"Aptiom","author":"Pharmaceuticals","year":"2017"},{"issue":"3","key":"10.1016\/j.cll.2026.07.010_bib33","first-page":"381","article-title":"Eslicarbazepine overdosing in a teenager: case description and management","volume":"30","author":"Kavga","year":"2025","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.cll.2026.07.010_bib34","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/FTD.0000000000000306","article-title":"The impact of pharmacokinetic interactions with eslicarbazepine acetate versus oxcarbazepine and carbamazepine in clinical practice","volume":"38","author":"Johannessen","year":"2016","journal-title":"Ther Drug Monit"},{"issue":"6","key":"10.1016\/j.cll.2026.07.010_bib35","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/j.1528-1167.2012.03519.x","article-title":"Pharmacokinetics and drug interactions of eslicarbazepine acetate","volume":"53","author":"Bialer","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.cll.2026.07.010_bib36","series-title":"The treatment of epilepsy","first-page":"398","article-title":"Benzodiazepines used in the treatment of epilepsy","author":"Trinka","year":"2015"},{"key":"10.1016\/j.cll.2026.07.010_bib37","doi-asserted-by":"crossref","first-page":"110261","DOI":"10.1016\/j.yebeh.2024.110261","article-title":"Antiseizure medications for lennox-gastaut syndrome: comprehensive review and proposed consensus treatment algorithm","volume":"164","author":"Samanta","year":"2025","journal-title":"Epilepsy Behav"},{"issue":"10","key":"10.1016\/j.cll.2026.07.010_bib38","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.braindev.2008.03.002","article-title":"Management of and prophylaxis against status epilepticus in children with severe myoclonic epilepsy in infancy (SMEI; dravet syndrome)--a nationwide questionnaire survey in Japan","volume":"30","author":"Tanabe","year":"2008","journal-title":"Brain Dev"},{"issue":"2","key":"10.1016\/j.cll.2026.07.010_bib39","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1212\/WNL.0000000000005756","volume":"91","author":"Kanner","year":"2018","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.cll.2026.07.010_bib40","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/epi.13852","article-title":"Interactions between cannabidiol and commonly used antiepileptic drugs","volume":"58","author":"Gaston","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.cll.2026.07.010_bib41","unstructured":"Lundbeck. 2024. Onfi [Package Insert]. Available at: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/Lundbeck."},{"issue":"4","key":"10.1016\/j.cll.2026.07.010_bib42","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/00002826-199408000-00004","article-title":"Aggression in children treated with clobazam for epilepsy","volume":"17","author":"Sheth","year":"1994","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.cll.2026.07.010_bib43","unstructured":"Park-Davis. 2021. Zarontin [Package Insert]. Available at: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/."},{"issue":"3","key":"10.1016\/j.cll.2026.07.010_bib44","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/0049825021000061606","article-title":"Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes","volume":"33","author":"Bachmann","year":"2003","journal-title":"Xenobiotica"},{"key":"10.1016\/j.cll.2026.07.010_bib45","series-title":"The treatment of epilepsy","first-page":"460","article-title":"Ethosuximide","author":"Glauser","year":"2015"},{"issue":"4","key":"10.1016\/j.cll.2026.07.010_bib46","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s13181-017-0626-4","article-title":"The pharmacology and toxicology of third-generation anticonvulsant drugs","volume":"13","author":"LaPenna","year":"2017","journal-title":"J Med Toxicol"},{"key":"10.1016\/j.cll.2026.07.010_bib47","unstructured":"GlaxoSmithKline. 2025. Lamictal [Package Insert]. Available at: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/."},{"issue":"2","key":"10.1016\/j.cll.2026.07.010_bib48","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/15563650.2017.1370096","article-title":"Acute lamotrigine overdose: a systematic review of published adult and pediatric cases","volume":"56","author":"Alyahya","year":"2018","journal-title":"Clin Toxicol (Phila)"},{"issue":"1","key":"10.1016\/j.cll.2026.07.010_bib49","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/epi4.12475","article-title":"FDA safety warning on the cardiac effects of lamotrigine: an advisory from the Ad Hoc ILAE\/AES task force","volume":"6","author":"French","year":"2021","journal-title":"Epilepsia Open"},{"issue":"5","key":"10.1016\/j.cll.2026.07.010_bib50","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s13312-025-00050-4","article-title":"Advances in neonatal seizures (2024): an update for pediatricians","volume":"62","author":"Elwadhi","year":"2025","journal-title":"Indian Pediatr"},{"issue":"10","key":"10.1016\/j.cll.2026.07.010_bib51","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1111\/epi.17745","article-title":"Treatment of seizures in the neonate: guidelines and consensus-based recommendations-special report from the ILAE task force on neonatal seizures","volume":"64","author":"Pressler","year":"2023","journal-title":"Epilepsia"},{"key":"10.1016\/j.cll.2026.07.010_bib52","series-title":"The treatment of epilepsy","first-page":"555","article-title":"Phenobarbital, primidone, and other barbiturates","author":"Michelucci","year":"2015"},{"key":"10.1016\/j.cll.2026.07.010_bib53","unstructured":"Sun Pharmaceutical Medicare Ltd. 2022, Sezaby [Package Insert], Available at: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/."},{"issue":"5","key":"10.1016\/j.cll.2026.07.010_bib54","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1542\/peds.61.5.728","article-title":"Behavior disturbance, phenobarbital, and febrile seizures","volume":"61","author":"Wolf","year":"1978","journal-title":"Pediatrics"},{"issue":"11","key":"10.1016\/j.cll.2026.07.010_bib55","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/jp.2013.116","article-title":"Adverse neurodevelopmental outcomes after exposure to phenobarbital and levetiracetam for the treatment of neonatal seizures","volume":"33","author":"Maitre","year":"2013","journal-title":"J Perinatol"},{"issue":"9","key":"10.1016\/j.cll.2026.07.010_bib56","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1007\/s00381-019-04286-x","article-title":"Neurodevelopmental outcomes at 9-14 months gestational age after treatment of neonatal seizures due to brain injury","volume":"35","author":"Ghosh","year":"2019","journal-title":"Childs Nerv Syst"},{"key":"10.1016\/j.cll.2026.07.010_bib57","series-title":"The treatment of epilepsy","first-page":"652","article-title":"Valproate","author":"Marson","year":"2015"},{"issue":"3","key":"10.1016\/j.cll.2026.07.010_bib58","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s002210000443","article-title":"Molecular regulation of glutamate and GABA transporter proteins by valproic acid in rat hippocampus during epileptogenesis","volume":"133","author":"Ueda","year":"2000","journal-title":"Exp Brain Res"},{"key":"10.1016\/j.cll.2026.07.010_bib59","unstructured":"AbbVie Inc. 2026. Depakote [Package Insert]. Available at: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/."},{"issue":"2","key":"10.1016\/j.cll.2026.07.010_bib60","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s12028-018-0627-4","article-title":"Accuracy of valproic acid concentration correction based on serum albumin","volume":"30","author":"Drisaldi","year":"2019","journal-title":"Neurocrit Care"},{"key":"10.1016\/j.cll.2026.07.010_bib61","series-title":"Disposition of TOxic drugs and chemicals in man","first-page":"2200","article-title":"Valproic acid","author":"Baselt","year":"2020"},{"issue":"10","key":"10.1016\/j.cll.2026.07.010_bib62","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s40262-022-01171-w","article-title":"Clinical pharmacokinetic monitoring of free valproic acid levels: a systematic review","volume":"61","author":"Lin","year":"2022","journal-title":"Clin Pharmacokinet"},{"issue":"15","key":"10.1016\/j.cll.2026.07.010_bib63","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.clinbiochem.2013.06.012","article-title":"Adverse drug reactions induced by valproic acid","volume":"46","author":"Nanau","year":"2013","journal-title":"Clin Biochem"},{"key":"10.1016\/j.cll.2026.07.010_bib64","series-title":"Ellenhorn's medical toxicology","first-page":"693","article-title":"Anticonvulsants","author":"Ellenhorn","year":"1997"},{"issue":"1","key":"10.1016\/j.cll.2026.07.010_bib65","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200210","article-title":"Zonisamide: a comprehensive, updated review for the clinician","volume":"14","author":"Gidal","year":"2024","journal-title":"Neurol Clin Pract"},{"issue":"6","key":"10.1016\/j.cll.2026.07.010_bib66","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/00007691-199812000-00001","article-title":"Clinical pharmacology and therapeutic drug monitoring of zonisamide","volume":"20","author":"Mimaki","year":"1998","journal-title":"Ther Drug Monit"},{"issue":"6","key":"10.1016\/j.cll.2026.07.010_bib67","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1055\/s-0034-1387815","article-title":"Zonisamide: pharmacokinetics, efficacy, and adverse events in children with epilepsy","volume":"45","author":"Wallander","year":"2014","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.cll.2026.07.010_bib68","unstructured":"Dainippon Pharmaceutical Co. Ltd. 2020. Zonegran [Package Insert]. Available at: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/"},{"key":"10.1016\/j.cll.2026.07.010_bib69","unstructured":"Janssen Pharmaceuticals, Inc. 2026. Topamax [Package Insert]. Available at: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/."},{"key":"10.1016\/j.cll.2026.07.010_bib70","unstructured":"Subramonian A, F.K., Brivaracetam versus levetiracetam for epilepsy: a review of comparative clinical safety, C.A.f.D.a.T.i. Health, Editor. 2020."},{"issue":"7","key":"10.1016\/j.cll.2026.07.010_bib71","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE commission on therapeutic strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"issue":"Suppl 9","key":"10.1016\/j.cll.2026.07.010_bib72","first-page":"S7","article-title":"The clinical pharmacokinetics of the new antiepileptic drugs","volume":"40","author":"Perucca","year":"1999","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.cll.2026.07.010_bib73","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/FTD.0b013e31827ada88","article-title":"Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies","volume":"35","author":"de Leon","year":"2013","journal-title":"Ther Drug Monit"},{"issue":"1","key":"10.1016\/j.cll.2026.07.010_bib74","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1248\/cpb.40.193","article-title":"Factors influencing serum concentration of zonisamide in epileptic patients","volume":"40","author":"Kimura","year":"1992","journal-title":"Chem Pharm Bull (Tokyo)"},{"issue":"12","key":"10.1016\/j.cll.2026.07.010_bib75","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s40262-015-0298-7","article-title":"Effect of kidney function on drug kinetics and dosing in neonates, infants, and children","volume":"54","author":"Rodieux","year":"2015","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.cll.2026.07.010_bib76","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FTD.0b013e31825ee389","article-title":"Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication","volume":"34","author":"Johannessen Landmark","year":"2012","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.cll.2026.07.010_bib77","series-title":"Medical genetics summaries","article-title":"Lacosamide therapy and CYP2C19 genotype","author":"Dean","year":"2012"},{"key":"10.1016\/j.cll.2026.07.010_bib78","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/TCRM.S5189","article-title":"Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety","volume":"5","author":"Kellinghaus","year":"2009","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"10.1016\/j.cll.2026.07.010_bib79","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3325\/cmj.2018.59.13","article-title":"Effect of antiepileptic drug comedication on lamotrigine concentrations","volume":"59","author":"Lovri\u0107","year":"2018","journal-title":"Croat Med J"},{"issue":"12","key":"10.1016\/j.cll.2026.07.010_bib80","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1176\/appi.ajp-rj.2018.131201","article-title":"Lamotrigine: pharmacology, clinical utility, and new safety concerns","volume":"13","author":"Mufson","year":"2026","journal-title":"Am J Psychiatry Resid J"},{"key":"10.1016\/j.cll.2026.07.010_bib81","series-title":"StatPearls [Internet]","article-title":"Valproic acid","author":"Rahman","year":"2026"},{"key":"10.1016\/j.cll.2026.07.010_bib82","series-title":"Zonisamide","author":"Kadian","year":"2025"}],"container-title":["Clinics in Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271226000806?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271226000806?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:40:51Z","timestamp":1792593651000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272271226000806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":82,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S0272271226000806"],"URL":"https:\/\/doi.org\/10.1016\/j.cll.2026.07.010","relation":{},"ISSN":["0272-2712"],"issn-type":[{"value":"0272-2712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-Seizure Medication Monitoring in Pediatric Patients","name":"articletitle","label":"Article Title"},{"value":"Clinics in Laboratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cll.2026.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}